CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- PositionGross margin is 89.8%, higher than 95% of its Medical Devices peers (median 61.5%)
- Interpretations8 currently firing — 8
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
541.30MUSDvs all stocks (USD)
Revenue (TTM)
95.42MUSDvs all stocks (USD)
Profit Margin
0.56%vs Medical Devices peers
Beta
0.5660xvs all stocks
52-Week Change
43.12%vs all stocks
Market Capitalization
541.30MUSDvs all stocks (USD)
Enterprise Value
447.86MUSDvs all stocks (USD)
Forward P/E
346.67xvs Medical Devices peers
Price to Sales (TTM)
5.67xvs Medical Devices peers
Price to Book (MRQ)
4.46xvs Medical Devices peers
Enterprise to Revenue
4.69xvs Medical Devices peers
Gross Margin
89.75%vs Medical Devices peers
Profit Margin
0.56%vs Medical Devices peers
Operating Margin
8.22%vs Medical Devices peers
Return on Assets (TTM)
-0.89%vs Medical Devices peers
Return on Equity (TTM)
0.47%vs Medical Devices peers
Revenue (TTM)
95.42MUSDvs all stocks (USD)
Revenue per Share (TTM)
2.64USDUpdated Sep 27, 2026Quarterly Revenue Growth
20.60%vs Medical Devices peers
Gross Profit (TTM)
83.06MUSDvs all stocks (USD)
EBITDA (TTM)
1.01MUSDvs all stocks (USD)
Net Income (TTM)
532.00KUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-1.10%vs Medical Devices peers
Operating Cash Flow (TTM)
19.59MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
18.12MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
85.23MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
11.80MUSDFY2025 · Dec 31, 2025Gross Profit
73.43MUSDFY2025 · Dec 31, 2025Operating Income
660.00KUSDvs all stocks (USD)
Pre-tax Income
3.51MUSDFY2025 · Dec 31, 2025Income Tax Expense
810.00KUSDFY2025 · Dec 31, 2025Net Income
2.70MUSDFY2025 · Dec 31, 2025EBIT
660.00KUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
1.01MUSDFY2025 · Dec 31, 2025Research & Development
29.25MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
43.53MUSDFY2025 · Dec 31, 2025EPS (Basic)
0.0800USDFY2025 · Dec 31, 2025EPS (Diluted)
0.0700USDFY2025 · Dec 31, 2025Basic Shares Outstanding
35.82MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
35.82MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
2.70MUSDFY2025 · Dec 31, 2025Operating Cash Flow
27.63MUSDFY2025 · Dec 31, 2025Free Cash Flow
26.09MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
43.45MUSDFY2025 · Dec 31, 2025Income Tax Paid
1.54MUSDFY2025 · Dec 31, 2025Interest Paid
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
2.70MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
349.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
24.23MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-854.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
4.77MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-3.56MUSDFY2025 · Dec 31, 2025Capital Expenditures
-1.55MUSDFY2025 · Dec 31, 2025Purchase of Investments
-93.22MUSDFY2025 · Dec 31, 2025Sale of Investments
68.17MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-26.59MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Common Stock Repurchase
-6.00MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-5.52MUSDFY2025 · Dec 31, 2025Shares Outstanding
34.64MSharesUpdated Sep 27, 2026Float Shares
28.78MSharesUpdated Sep 27, 2026Shares Short
2.31MSharesUpdated Sep 27, 2026Short Ratio
5.78daysvs all stocks
Short % of Shares Outstanding
7.25%vs all stocks
% Held by Insiders
8.09%vs all stocks
% Held by Institutions
51.78%vs all stocks
Total Cash (MRQ)
95.90MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.76USDUpdated Sep 27, 2026Total Debt (MRQ)
2.46MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0203xvs Medical Devices peers
Current Ratio (MRQ)
9.83xvs Medical Devices peers
Book Value per Share (MRQ)
3.50USDUpdated Sep 27, 2026Total Assets
123.63MUSDvs all stocks (USD)
Total Current Assets
119.53MUSDFY2025 · Dec 31, 2025Total Liabilities
12.41MUSDFY2025 · Dec 31, 2025Total Non-current Assets
4.10MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
1.46MUSDFY2025 · Dec 31, 2025Total Current Liabilities
10.95MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
43.45MUSDFY2025 · Dec 31, 2025Other Short-term Investments
47.58MUSDFY2025 · Dec 31, 2025Accounts Receivable
11.74MUSDFY2025 · Dec 31, 2025Inventory
10.25MUSDFY2025 · Dec 31, 2025Accounts Payable
2.66MUSDFY2025 · Dec 31, 2025Short-term Debt
101.00KUSDFY2025 · Dec 31, 2025Long-term Debt
835.00KUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
628.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
347.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-528.85MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
111.22MUSDvs all stocks (USD)
52-Week Low
8.12USDUpdated Sep 27, 202652-Week High
17.42USDUpdated Sep 27, 202652-Week Change
43.12%vs all stocks
Beta
0.5660xvs all stocks
50-Day MA
15.23USDUpdated Sep 27, 2026200-Day MA
11.71USDUpdated Sep 27, 2026Avg 10-Day Volume
398.15KSharesUpdated Sep 27, 2026Avg 30-Day Volume
402.95KSharesUpdated Sep 27, 2026Diluted EPS (TTM)
0.0100USDUpdated Sep 27, 2026Other Income / Expense
-70.00KUSDFY2025 · Dec 31, 20258 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
How does this company use capital?
Cash-Backed Growth Configuration
Revenue has grown steadily, and the cash arriving matches reported profit.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
Where is this company structurally exposed?
SBC-to-Net-Income Elevated, SBC-to-Revenue Elevated, And Diluted Share Count Growing (6Y CAGR)
Pay in shares is large next to its revenue and its profit, and the share count keeps rising.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 89.8%, higher than 95% of its Medical Devices peers (median 61.5%)Significant
Gross margin: 0.90Industry median: 0.62Industry P95: 0.85Peers compared: 102
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.90Profit Margin: 0.01
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Orchid Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pharmicell Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai Shen Lian Bio-Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
BrainsWay Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Lifecome Biochemistry Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
TaiMed Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Bliss GVS Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhuhai Rundu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
CHA Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleInterface
Kingchem Liaoning Life Science Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
One Career Inc.
6 interpretationsCash-Backed Growth ConfigurationFCF Ratios ElevatedCash-Flow Ratios ElevatedCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedLow-Leverage Liquidity Configuration
Jiangsu Nanfang Precision Co., Ltd.
5 interpretationsFCF Ratios ElevatedCash-Flow Ratios ElevatedCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedLow-Leverage Liquidity Configuration
Credo Technology Group Holding Ltd.
5 interpretationsFCF Ratios ElevatedCash-Flow Ratios ElevatedCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedLow-Leverage Liquidity Configuration